Activity and safety of combination chemotherapy with methotrexate, ifosfamide, L-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: A pilot study

European Journal of Haematology

Volumn 84, Issue 4, 2010, Pages 310-315

  Tsukune, Yutaka ^a   Isobe, Yasushi ^a   Yasuda, Hajime ^a   Shimizu, Seiichi ^b   Katsuoka, Yuna ^b,c   Hosone, Masaru ^d   Oshimi, Kazuo ^a   Komatsu, Norio ^a   Sugimoto, Koichi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TSUCHIURA KYODO GENERAL HOSPITAL   (Japan)

^c SENDAI CITY MEDICAL CENTER   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

L asparaginase; Lymphopenia; Methotrexate; Salvage chemotherapy; T NK cell malignancy

Indexed keywords

ASPARAGINASE; CARBOPLATIN; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GLYCOPROTEIN P; IFOSFAMIDE; INTERFERON; IRINOTECAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BLASTIC NK CELL LYMPHOMA; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CORD BLOOD STEM CELL TRANSPLANTATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HAIRY CELL LEUKEMIA; HERPES ZOSTER; HUMAN; HYPERBILIRUBINEMIA; HYPOFIBRINOGENEMIA; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; MUCORMYCOSIS; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PLEURA EFFUSION; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; SIDE EFFECT; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS INFECTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IFOSFAMIDE; LYMPHOPENIA; MALE; METHOTREXATE; MIDDLE AGED; MUCORMYCOSIS; NEUTROPENIA; PILOT PROJECTS;

EID: 77949507222     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01395.x     Document Type: Article

References (19)

1. Messori A, Vaiani M, Trippoli S, et al. Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001;84:303-7.
2. International T-cell lymphoma project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcome. J Clin Oncol 2008;26:4120-6.
3. Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:5165-9.
4. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
5. Liu Q, Oshima K, Kikuchi M. High expression of MDR-1 gene and P-glycoprotein in initial and re-biopsy specimens of relapsed B-cell lymphoma. Histopathology 2001;38:209-16.
6. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma. Cancer 1996;76:2351- 6.
7. Zelenetz AD, Hamlin P, Kewalramani J, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2003;14(Suppl. 1):i5-10.
8. Stamatoullas A, Fruchart C, Bastit D, et al. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer 1996;77:2302- 7.
9. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17: 1244-53.
10. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute working group 1996 guidelines. Blood 2008;111:5446-56.
11. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-78.
12. Kamen BA. l-asparaginase and methotrexate combinations: clashes of empiric success and laboratory models? J Pediatr Hematol Oncol 2007;29:587-8.
13. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC?NCRI LY10 trial). Blood 2008;112:2248-60.
14. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2007;8(Suppl. 2):S57-62.
15. Deangelis LM, Iwamoto FM. An update on therapy of primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2006;311-6.
16. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advancedstage, relapsed or refractory extranodal natural killer (NK)?T-cell lymphoma and leukemia. Cancer Sci 2008;99:1016-20.
17. Jaccard A, Petit B, Girault S, et al. L-asparaginase- based treatment of 15 western patients with extranodal NK? T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 2008;20:110-6.
18. Talaulikar D, Choudhury A, Shadbolt B, Brown M. Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. Leuk Lymphoma 2008;49:959-64.
19. Mounier N, Spina M, Gisselbrecht C. Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol 2007;136:685-98.